Boston Scientific (BSX) Stock
Global medical device company powering heart and urology care. Here's the price, business snapshot, and what's worth knowing about Boston Scientific in May 2026.
Boston Scientific (BSX) is a global medical‑devices company with a market capitalisation of about $148.03bn, selling products used in cardiology, rhythm management, peripheral interventions, endoscopy and urology. Investors should know it earns recurring revenue from disposable devices and procedure-driven demand, backed by ongoing R&D and product launches. The business benefits from demographic trends such as an ageing population and wider access to minimally invasive therapies, yet it faces stiff competition from large peers, reimbursement and regulatory pressures, and occasional product or legal setbacks. Financial performance can be influenced by procedure volumes, hospital capital spending, foreign exchange and the success of new technologies. For investors, Boston Scientific offers exposure to healthcare innovation but also to sector-specific operational and regulatory risks. This is general educational information, not personalised advice — values can rise and fall and past performance is not a reliable guide to future returns.
Why It's Moving
BSX is drawing support as analysts point to durable growth and a favorable medical-device backdrop.
- Analyst coverage remains skewed positive, signaling confidence that Boston Scientific’s product mix and execution can keep revenue growth ahead of the broader market.
- Recent forecasts have emphasized steady earnings power and cash generation, which can make the stock more attractive in a market that rewards visible growth and resilience.
- The broader medical-devices sector continues to benefit from aging demographics and ongoing procedure volumes, giving BSX a supportive backdrop even without a major fresh catalyst in the last week.
BSX is drawing support as analysts point to durable growth and a favorable medical-device backdrop.
- Analyst coverage remains skewed positive, signaling confidence that Boston Scientific’s product mix and execution can keep revenue growth ahead of the broader market.
- Recent forecasts have emphasized steady earnings power and cash generation, which can make the stock more attractive in a market that rewards visible growth and resilience.
- The broader medical-devices sector continues to benefit from aging demographics and ongoing procedure volumes, giving BSX a supportive backdrop even without a major fresh catalyst in the last week.
When is the next earnings date for BOSTON SCIENTIFIC CORP (BSX)?
The next earnings date for Boston Scientific (BSX) is expected on July 29, 2026 before the market open. It will cover Q2 2026 results. The company has not formally confirmed the date, but this timing matches the usual quarterly reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Boston Scientific stock, anticipating significant growth potential ahead.
Financial Health
Boston Scientific is performing well with strong profits, cash flow, and revenue growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BSX
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketStagflation Standouts
This collection features stocks and assets carefully selected by professional analysts to potentially outperform during stagflation periods. These defensive investments have already shown strength while the broader market struggles, making them worth consideration for economic uncertainty ahead.
Published: May 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Procedure demand tailwind
An ageing population and rising access to minimally invasive procedures can support long‑term demand, though volumes can ebb with hospital spending cycles.
Innovation and R&D
Regular product launches and technological improvements drive share gains and pricing power, but new products must clear regulatory and commercial hurdles.
Regulatory and market risks
Exposure to reimbursement, recalls and litigation means performance can be volatile; investors should weigh potential returns against these sector‑specific risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
